From an accidental discovery to rational drug design: Aspergillus fumigatus and angiogenesis;Von einer zufallsentdeckung zum rationalen drug-design: Aspergillus fumigatus und angiogenese

Pharmazie in Unserer Zeit

Volumn 36, Issue 6, 2007, Pages 450-451

  Klein, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FUMAGILLIN; METHIONYL AMINOPEPTIDASE; PROBIOTIC AGENT; PROTEIN P53;

ANGIOGENESIS; ARTICLE; ASPERGILLUS FUMIGATUS; COVALENT BOND; DRUG DESIGN; ENZYME INHIBITION; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ASPERGILLUS FUMIGATUS; CYCLOHEXANES; FATTY ACIDS, UNSATURATED; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SESQUITERPENES;

EID: 36349013819     PISSN: 00483664     EISSN: 16151003     Source Type: Journal    
DOI: 10.1002/pauz.200700242     Document Type: Article

References (10)

1. Ingber, D., et al.: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348 (1990), 555-557.
2. McCowen, M.C., Callender, M.E., Lawlis, J.F.: Fumagillin (H-3), a New Antibiotic with Amebicidal Properties. Science 113 (1951), 202-203.
3. Griffith, E.C., et al.: Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. 4 (1997), 461-471.
4. Sin, N., Meng, L., Wang, M.Q., Wen, J.J., Bornmann, W.G., Crews, C.M.: The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase MetAP-2. Proc. Natl. Acad. Sci. USA 94 (1997), 6099-6103.
5. Liu, S., et al.: Structure of Human Methionine Aminopeptidase-2 Complexed with Fumagillin. Science 282 (1998), 1324-1327.
6. Lowther, W.T., et al.: The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase. Proc. Natl. Acad. Sci. USA 95 (1998), 12153-12157.
7. Yeh, J.R.J., Mohan, R., Crews, C.M.: The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc. Natl. Acad. Sci. USA 97 (2000), 12782-12787.
8. Wernert, N., et al.: Inhibition of Angiogenesis In Vivo by ets-1 Antisense Oligonucleotides - Inhibition of Ets-1 Transcription Factor Expression by the Antibiotic Fumagillin. Angew. Chem. Int. Ed. Engl. 38 (1999), 3228-3231.
9. Zhang, Y., et al.: Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc. Natl. Acad. Sci. USA 97 (2000), 6427-6432.
10. Chen, G.J., et al.: FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug Fumagillin (TNP-470). J. Cell. Biochem. (2007), Feb 12; [Epub ahead of print].